跳至主要内容

Anti-M3 Muscarinic Acetylcholine Receptor Antibodies in Systemic Lupus Erythematosus

Read  full  paper  at:
http://www.scirp.org/journal/PaperInformation.aspx?PaperID=53383#.VMBovizQrzE

ABSTRACT
Background: Evidences have shown that anti-M3 muscarinic acetylcholine receptor IgG (anti-M3 mAChR IgG) are clinically useful autoantibody that exert a cholinergic pharmacologic effect binding and interacting with M3 mAChR at the level of exocrine gland (salivary and ocular). Aims: The aim of this study was to determine the associations between serum level of anti-M3 mAChR IgG in patients with systemic lupus erythematosus (SLE) and other autoantibodies, serum prostaglandin E2 (PGE2), and clinical manifestations. Methods: Serum autoantibodies against M3 mAChR synthetic peptide were measured by enzyme-linked immuno absorbent assay (ELISA) using, as an antigen, a 25-mer peptide K-R-T-V-P-D-N-Q-C-F-I-Q-F-L-S-N-P-A-V-T-F-G-T-A-I corresponding to the amino acid sequence of the second extracellular loop of the human M3 mAChR. Serum levels of antinuclear antibodies (ANA), anti-Smith (Sm) antibodies, anti-phospholipid (APL) antibodies, and PGE2 were determined by ELISA in patients with SLE. Results: We found significantly enhanced titers of anti-M3 mAChR IgG in sera from SLE patients compared with healthy individuals (control). In addition, serum levels of PGE2 were significantly higher in SLE patients than in control patients and were significantly higher in active than in non-active SLE. No correlation was found with other autoantibodies present in SLE. By contrast, a positive correlation was found between anti-M3 mAChR IgG and PGE2 serum levels in SLE. Conclusions: As anti-M3 mAChR antibodies present in the sera of SLE patients may be another factor in the pathogenesis of this disease, and the increment of PGE2 in the sera of SLE has a modulatory action on the inflammatory process, suggesting that the presence of these autoantibodies against M3 mAChR may contribute to sustained immune deregulation and the strong inflammatory component observed in SLE.
 
Cite this paper
Reina, S. , Pisoni, C. , Eimon, A. , Carrizo, C. , Arana, R. and Borda, E. (2015) Anti-M3 Muscarinic Acetylcholine Receptor Antibodies in Systemic Lupus Erythematosus. Pharmacology & Pharmacy, 6, 25-33. doi: 10.4236/pp.2015.61004.
 
References
[1]Deane, K.D. (2014) Preclinical Rheumatoid Arthritis (Autoantibodies): An Updated Review. Current Rheumatology Report, 16, 419-422.
http://dx.doi.org/10.1007/s11926-014-0419-6
 
[2]Bizzaro, N. (2007) Autoantibodies as Predictors of Disease: The Clinical and Experimental Evidence. Autoimmunity Review, 6, 325-333.
http://dx.doi.org/10.1016/j.autrev.2007.01.006
 
[3]Bizzaro, N. (2008) The Predictive Significance of Autoanti-bodies in Organ-Specific Autoimmune Diseases. Clinical Reviews in Allergy & Immunology, 34, 326-331.
http://dx.doi.org/10.1007/s12016-007-8059-5
 
[4]Sherer, Y., Gorstein, A., Fritzler, M.J. and Shoenfeld, Y. (2004) Autoantibody Explosion in Systemic Lupus Erythematosus: More than 100 Different Antibodies Found in SLE Patients. Seminars in Arthritis and Rheumatism, 34, 501-537.
http://dx.doi.org/10.1016/j.semarthrit.2004.07.002
 
[5]Li, Q.Z., Zhou, J., Wandstrat, A.E., Carr-Johnson, F., Branch, V. and Karp, D.R. (2007) Protein Array Autoantibody Profiles for Insights into Systemic Lupus Erythematosus and Incomplete Lupus Syndromes. Clinical Experimental Immunology, 147, 60-70.
 
[6]Mansour, R.B., Lassoued, S., Gargouri, B., El Gaid, A., Attia, H. and Fakhfakh, F. (2008) Increased Levels of Autoantibodies against Catalase and Superoxide Dismutase Associated with Oxidative Stress in Patients with Rheumatoid Arthritis and Systemic Lupus Erythematosus. Scandinavian Journal of Rheumatology, 37, 103-108.
http://dx.doi.org/10.1080/03009740701772465
 
[7]Magalhaes, M.B., da Silva, L.M., Voltarelli, J.C., Donadi, E.A. and Louzada-Junior, P. (2007) Lymphocytotoxic Antibodies in Systemic Lupus Erythematosus Are Associated with Disease Activity Irrespective of the Presence of Neuropsychiatric Manifestations. Scandinavian Journal of Rheumatology, 6, 442-447.
http://dx.doi.org/10.1080/03009740701482768
 
[8]Braun, A., Sis, J., Max, R., Mueller, K., Fiehn, C., Zeier, M. and Andrassy, K. (2007) Anti-Chromatin and Anti-C1q Antibodies in Systemic Lupus Erythematosus Compared to Other Systemic Autoimmune Diseases. Scandinavian Journal of Rheumatology, 36, 291-298.
http://dx.doi.org/10.1080/03009740701218717
 
[9]D’Cruz, D.P., Khamashta, M.A. and Hughes, G.R. (2007) Systemic Lupus Erythematosus. Lancet, 369, 587-596.
http://dx.doi.org/10.1016/S0140-6736(07)60279-7
 
[10]Rahman, A. and Isenberg, D.A. (2008) Systemic Lupus Erythematosus. New England Journal of Medicine, 358, 929-939.
http://dx.doi.org/10.1056/NEJMra071297
 
[11]Pugh-Bernard, A.E. and Cambier, J.C. (2006) B Cell Receptor Signaling in Human Systemic Lupus Erythematosus. Current Opinion in Rheumatology, 18, 451-455.
http://dx.doi.org/10.1097/01.bor.0000240353.99808.5f
 
[12]Nagy, G., Koncz, A. and Perl, A. (2005) T- and B-Cell Abnormalities in Systemic Lupus Erythematosus. Critical Reviews in Immunology, 25, 123-140.
http://dx.doi.org/10.1615/CritRevImmunol.v25.i2.30
 
[13]Ishikawa, S., Akakura, S., Abe, M., Terashima, K., Chijiiwa, K., Nishimura, H., Hirose, S. and Shirai, T. (1998) A Subset of CD4+ T Cells Expressing Early Activation Antigen CD69 in Murine Lupus: Possible Abnormal Regulatory Role for Cytokine Imbalance. Journal of Immunology, 161, 1267-1273.
 
[14]Bohm, I. (2004) Apoptosis: The Link between Autoantibodies and Leuko-/Lymphocytopenia in Patients with Lupus Erythematosus. Scandinavian Journal of Rheumatology, 33, 409-416.
http://dx.doi.org/10.1080/03009740410006907
 
[15]Reichlin, M. (1993) Antibodies to Defined Antigens in the Systemic Rheumatic Diseases. Bulletin on the Rheumatic Diseases, 42, 4-6.
 
[16]Waltuck, J. and Buyon, J.P. (1994) Autoantibody-Associated Congenital Heart Block: Outcome in Mothers and Children. Annals of Internal Medicine, 120, 544-551.
http://dx.doi.org/10.7326/0003-4819-120-7-199404010-00003
 
[17]Aho, K., Koskela, P., Makitalo, R., Heliovaara, M. and Palosuo, T. (1992) Antinuclear Antibodies Heralding the Onset of Systemic Lupus Erythematosus. Journal of Rheumatology, 19, 1377-1379.
 
[18]Heinlen, L.D., McClain, M.T., Merrill, J., Akbarali, Y.W., Edgerton, C.C., Harley, J.B. and James, J.A. (2007) Clinical Criteria for Systemic Lupus Erythematosus Precede Diagnosis, and Associated Autoantibodies Are Present before Clinical Symptoms. Arthritis & Rheumatism, 56, 2344-2351.
http://dx.doi.org/10.1002/art.22665
 
[19]McClain, M.T., Arbuckle, M.R., Heinlen, L.D., Dennis, G.J., Roebuck, J., Rubertone, M.V., Harley, J.B. and James, J.A. (2004) The Prevalence, Onset, and Clinical Significance of Antiphospholipid Antibodies Prior to Diagnosis of Systemic Lupus Erythematosus. Arthritis & Rheumatism, 50, 1226-1232.
http://dx.doi.org/10.1002/art.20120
 
[20]Heinlen, L.D., McClain, M.T., Ritterhouse, L.L., Bruner, B.F., Edgerton, C.C., Keith, M.P., James, J.A. and Harley, J.B. (2010) 60 kD Ro and nRNP A Frequently Initiate Human Lupus Autoimmunity. PLoS ONE, 5, e9599.
http://dx.doi.org/10.1371/journal.pone.0009599
 
[21]Arbuckle, M.R., McClain, M.T., Rubertone, M.V., Scofield, R.H., Dennis, G.J., James, J.A. and Harley, J.B. (2003) Development of Autoantibodies before the Clinical Onset of Systemic Lupus Erythematosus. New England Journal of Medicine, 349, 1526-1533.
http://dx.doi.org/10.1056/NEJMoa021933
 
[22]Arbuckle, M.R., James, J.A., Kohlhase, K.F., Rubertone, M.V., Dennis, G.J. and Harley, J.B. (2001) Development of Anti-dsDNA Autoantibodies Prior to Clinical Diagnosis of Systemic Lupus Erythematosus. Scandinavian Journal of Immunology, 54, 211-219.
http://dx.doi.org/10.1046/j.1365-3083.2001.00959.x
 
[23]Jonsson, R., Theander, E., Sjöström, B., Brokstad, K. and Henriksson, G. (2013) Autoantibodies Present before Symptom Onset in Primary Sjögren Syndrome. JAMA, 310, 1854-1855.
http://dx.doi.org/10.1001/jama.2013.278448
 
[24]Tzioufas, A.G., Kapsogeorgou, E.K. and Moutsopoulos, H.M. (2012) Pathogenesis of Sjögren’s Syndrome: What We Know and What We Should Learn. Journal of Autoimmunity, 39, 4-8.
http://dx.doi.org/10.1016/j.jaut.2012.01.002
 
[25]Reina, S., Sterin-Borda, L., Orman, B. and Borda, E. (2004) Autoantibodies against Cerebral Muscarinic Cholinoceptors in Sjögren Syndrome: Functional and Pathological Implications. Journal of Neuroimmunology, 150, 107-115.
http://dx.doi.org/10.1016/j.jneuroim.2004.01.019
 
[26]Reina, S., Sterin-Borda, L. and Borda, E. (2012) Anti-M3 Peptide IgG from Sjögren’s Syndrome Triggers Apoptosis in A253 Cells. Cellular Immunology, 275, 33-41.
http://dx.doi.org/10.1016/j.cellimm.2012.03.006
 
[27]Chae, B.S., Shin, T.Y., Kim, D.K., Eun, J.S., Leem, J.Y. and Yang, J.H. (2008) Prostaglandin E2-Mediated Dysregulation of Proinflammatory Cytokine Production in Pristane-Induced Lupus Mice. Archives of Pharmacal Research, 31, 503-510.
http://dx.doi.org/10.1007/s12272-001-1185-6
 
[28]Abreu-Velez, A.M., Smith Jr., G. and Howard, M.S. (2011) Activation of the Signaling Cascade in Response to T Lymphocyte Receptor Stimulation and Prostanoids in a Case of Cutaneous Lupus. North American Journal of Medical Sciences, 3, 251-254.
http://dx.doi.org/10.4297/najms.2011.3251
 
[29]Tan, E.M., Cohen, A.S., Fries, J.F., Masi, A.T., McShane, D.J., Rothfield, N.F., Schaller, J.G., Talal, N. and Winchester, R.J. (1982) The 1982 Revised Criteria for the Classification of Systemic Lupus Erythematosus. Arthritis & Rheumatism, 25, 1271-1277.
http://dx.doi.org/10.1002/art.1780251101
 
[30]Bombardier, C., Gladman, D.D., Urowitz, M.B., Caron, D., Chang, C.H., et al., The Committee on Prognosis Studies in SLE (1992) Derivation of the Sledai. A Disease Activity Index for Lupus Patients. Arthritis & Rheumatism, 35, 630-640.
http://dx.doi.org/10.1002/art.1780350606
 
[31]Guzman, J., Cardiel, M.H., Arce-Salinas, A., Sánchez-Guerrero, J. and Alarcón-Segovia, D. (1992) Measurement of Disease Activity in Systemic Lupus Erythematosus. Prospective Validation of 3 Clinical Indices. Journal of Rheumatology, 19, 1551-1558.
 
[32]Eriksson, C., Kokkonen, H., Johansson, M., Hallmans, G., Wadell, G. and Rantapaa-Dahlqvist, S. (2011) Autoantibodies Predate the Onset of Systemic Lupus Erythematosus in Northern Sweden. Arthritis Research & Therapy, 13, R30-R34.
http://dx.doi.org/10.1186/ar3258
 
[33]Tsai, C.Y., Wu, T.H., Tsai, S.T., Chen, K.H., Thajeb, P., Lin, W.M., Yu, H.S. and Yu, C.L. (1994) Cerebrospinal Fluid Interleukin-6, Prostaglandin E2, and Autoantibodies in Patients with Neuropsychiatric Systemic Lupus Erythematosus and Central Nervous System Infections. Scandinavian Journal of Rheumatology, 23, 57-63.
http://dx.doi.org/10.3109/03009749409103028                                                 eww150122lx
标签：

评论

发表评论

此博客中的热门博文

A Comparison of Methods Used to Determine the Oleic/Linoleic Acid Ratio in Cultivated Peanut (Arachis hypogaea L.)

Cultivated peanut ( Arachis hypogaea L.) is an important oil and food crop. It is also a cheap source of protein, a good source of essential vitamins and minerals, and a component of many food products. The fatty acid composition of peanuts has become increasingly important with the realization that oleic acid content significantly affects the development of rancidity. And oil content of peanuts significantly affects flavor and shelf-life. Early generation screening of breeding lines for high oleic acid content greatly increases the efficiency of developing new peanut varieties. The objective of this study was to compare the accuracy of methods used to classify individual peanut seed as high oleic or not high oleic. Three hundred and seventy-four (374) seeds, spanning twenty-three (23) genotypes varying in oil composition (i.e. high oleic (H) or normal/not high oleic (NH) inclusive of all four peanut market-types (runner, Spanish, Valencia and Virginia), were individually tested ...
发表评论
阅读全文

Location Optimization of a Coal Power Plant to Balance Costs against Plant’s Emission Exposure

Fuel and its delivery cost comprise the biggest expense in coal power plant operations. Delivery of electricity from generation to consumers requires investment in power lines and transmission grids. Placing a coal power plant or multiple power plants near dense population centers can lower transmission costs. If a coalmine is nearby, transportation costs can also be reduced. However, emissions from coal plants play a key role in worsening health crises in many countries. And coal upon combustion produces CO 2 , SO 2 , NO x , CO, Metallic and Particle Matter (PM10 & PM2.5). The presence of these chemical compounds in the atmosphere in close vicinity to humans, livestock, and agriculture carries detrimental health consequences. The goal of the research was to develop a methodology to minimize the public’s exposure to harmful emissions from coal power plants while maintaining minimal operational costs related to electric distribution losses and coal logistics. The objective was...
发表评论
阅读全文

Evaluation of the Safety and Efficacy of Continuous Use of a Home-Use High-Frequency Facial Treatment Appliance

At present, many home-use beauty devices are available in the market. In particular, many products developed for facial treatment use light, e.g., a flash lamp or a light-emitting diode (LED). In this study, the safety of 4 weeks’ continuous use of NEWA TM , a high-frequency facial treatment appliance, every alternate day at home was verified, and its efficacy was evaluated in Japanese individuals with healthy skin aged 30 years or older who complained of sagging of the facial skin.  Transepidermal water loss (TEWL), melanin levels, erythema levels, sebum secretion levels, skin color changes and wrinkle improvement in the facial skin were measured before the appliance began to be used (study baseline), at 2 and 4 weeks after it had begun to be used, and at 2 weeks after completion of the 4-week treatment period (6 weeks from the study baseline). In addition, data obtained by subjective evaluation by the subjects themselves on a visual analog scale (VAS) were also analyzed. Fur...
发表评论
阅读全文